Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Zyban
|
| gptkbp:activities |
norepinephrine-dopamine reuptake inhibitor
|
| gptkbp:approves |
seasonal affective disorder
major depressive disorder |
| gptkbp:brand |
gptkb:Zyban
gptkb:Wellbutrin |
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:contraindication |
eating disorders
alcohol withdrawal seizure disorder |
| gptkbp:developed_by |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:dosage_form |
100 mg
400 mg 200 mg 300 mg |
| gptkbp:formulation |
oral tablet
extended-release tablet sustained-release tablet |
| gptkbp:healthcare |
gptkb:2006
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bupropion
|
| gptkbp:ingredients |
C13 H18 Cl N O2
|
| gptkbp:interacts_with |
MAO inhibitors
antipsychotics other antidepressants |
| gptkbp:is_atype_of |
N06 A X12
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_used_for |
gptkb:historical_event
anxiety disorders ADHD |
| gptkbp:lifespan |
21 hours
|
| gptkbp:metabolism |
liver
|
| gptkbp:requires |
prescription only
|
| gptkbp:research_areas |
clinical psychology
psychiatry neuropharmacology psychopharmacology addiction medicine |
| gptkbp:side_effect |
dizziness
nausea weight loss insomnia dry mouth |
| gptkbp:type_of |
34841-39-9
|
| gptkbp:year_created |
gptkb:1989
|